Brain Metastases clinical trials at UCSF
2 in progress, 0 open to eligible people
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Sorry, in progress, not accepting new patients
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.
San Francisco, California and other locations
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
Sorry, in progress, not accepting new patients
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy
San Francisco, California and other locations
Our lead scientists for Brain Metastases research studies include Javier Villanueva-Meyer Michelle Melisko.
Last updated: